Cupid targets Rs. 50 crore+ topline from B2C in FY 2024-25

Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market

Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure

Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%

DKSH partners with Hasten Biopharmaceutical’s growth in Thailand

Natco Pharma announces submission of TABRECTA to USFDA

TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA

Aptar Closures introduces new lightweight 2? Disc Top Lite Closure for beauty and personal care

The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options

Akums appoints Amrut Medhekar as CEO - CDMO Business

e brings over 27+ years of rich pharmaceutical experience

Shilpa Medicare announces positive outcome of Phase 3 studies of NorUDCA

Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India

Indoco Remedies receives final ANDA approval from the USFDA for Lofexidine Tablets 0.18 mg

This product will be manufactured by Indoco at its manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa in India

Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP

This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers

Marksans Pharma Q1 FY25 revenue up 18%

Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%